New drug - MEAI may curb excess drinking
Researchers have patented a drug that could produce some of ecstasy's euphoric effects and at the same time limit the amount of alcohol people drink.
Pharma News
Pfizer's Ibrance got accelerated approval from US FDA
U. S. Food and Drug Administration granted accelerated approval to palbociclib (IBRANCE, Pfizer, Inc.) for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
Arsenic in drinking water tied to drop in breast cancer deaths
A new study has found that high levels of arsenic in drinking water were associated with an "astonishing" 50 per cent drop in breast cancer deaths in Chile. The study presents results of breast cancer mortality data from a region in Chile where residents were inadvertently exposed to high levels of arsenic, a naturally occurring element found in many minerals.
Sun Pharma & Ranbaxy deal got US nod
Sun Pharma and Ranbaxy Laboratories announced that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Ranbaxy by Sun Pharma and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
Now a Phone sniffs out disease
A research consortium headed by Professor Hossam Haick of the Technion-Israel Institute of Technology is developing a product that, when coupled with a smartphone, will be able to screen the user’s breath for early detection of life-threatening diseases.
National Level Workshop on Industrial and Academic Perspectives of Regulatory Affairs to be held at Ali Allana College of Pharmacy, Akkalkuwa, Nandurbar
Jamia Islamia Isha Atul Uloom’s Ali Allana College of Pharmacy, Akkalkuwa, Dist. Nandurbar has organized national level workshop on “Industrial and Academic Perspectives of Regulatory Affairs in pharmaceutical industry.” This will be one day workshop on 10 February 2015 from time 10 am to 4.30 pm.
New compounds to treat virus causing respiratory illness
Researchers have identified a class of compounds that could help combat a virus which has stricken children with serious respiratory infections and is also associated with polio-like symptoms.
Jakavi found superior to standard therapy for Polycythemia Vera
Novartis announced results from the pivotal Phase III clinical trial demonstrating Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with polycythemia vera (PV) who had an inadequate response to or unacceptable side effects from hydroxyurea as defined according to the modified European LeukemiaNet (ELN) criteria, which is published in The New England Journal of Medicine (NEJM). In PV, hematocrit control and spleen size reduction are key measures of a patient's response to therapy.
Cholera bacterium kills other bacteria to steal their dna
Scientists have discovered the unconventional way the cholera bacterium stabs and kills other bacteria to steal their DNA, making it potentially more virulent. Cholera is caused when the bacterium Vibrio cholerae (V cholerae) infects the small intestine. The disease is characterised by acute watery diarrhea resulting in severe dehydration.
RESEARCHERS FIND NEW ROLE FOR PROTEINS
Scientists have found for the first time that the building blocks of a protein can be assembled by another protein and without genetic instructions. The findings defy textbook science which says DNA spells out the instructions for making proteins, tiny machines that do much of the work in our body's cells.
Recent Topics